Cutaneous melanoma is typically managed with surgery and rarely with topical chemotherapy and radiotherapy, whereas systemic checkpoint immunotherapy and BRAF-targeted or MEK-targeted therapies are used in advanced melanoma. This evidence concerns the gene MAP2K7 and melanoma.